Skip to content
value.today

Cynaptec Pharmaceuticals, Inc.

🇺🇸 Stuart, Florida, USABiotechnologyFounded 2025
Total raised
$6 M
1 round on record
Latest round
$6 M
Apr 2025
First round on record
Apr 2025
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Cynaptec Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2025$6 MNo. 1$2 to $10 million

Cynaptec Pharmaceuticals, Inc.: Raise no. 1, Apr 2025

Investors in this round

1 investor had bought by the notice of Apr 17, 2025: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $26 M offered; $20 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Frederick Sancilio · Executive Officer, Director
  • Charles F Goulburn Ii · Director
  • Jonah F Shacknai · Director
  • Seth F Rodner · Director
  • Wesley F Ramjeet · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Frederick Sancilio, Chief Executive Officer. Newest notice filed Apr 17, 2025. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Cynaptec Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2025).

    SEC Form D · Apr 2025

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Apr 2025

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Cynaptec Pharmaceuticals, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Cynaptec Pharmaceuticals, Inc.
NameRoleNamed in
Frederick SancilioExecutive officerApr 2025
Charles F Goulburn IiDirectorApr 2025
Frederick SancilioDirectorApr 2025
Jonah F ShacknaiDirectorApr 2025
Seth F RodnerDirectorApr 2025
Wesley F RamjeetDirectorApr 2025